重症新型冠状病毒肺炎患者抗病毒治疗的药物利用评价:洛匹那韦/利托那韦

Drug Utilization Evaluation on Antiviral Treatment in Patients with Severe Coronavirus Disease 2019:Lopinavir/ritonavir

目的对重症新型冠状病毒肺炎(COVID-19)患者治疗期间洛匹那韦/利托那韦(LPV/r)的临床使用现状进行分析,为临床合理使用提供参考。方法回顾性分析2020年2月1日-2月29日某重症COVID-19患者定点收治医院使用LPV/r的病例,对患者人口学特征、LPV/r剂量、用药时机、疗程、联合用药情况等进行统计分析。结果共有217例患者使用LPV/r,患者以老年人(>64岁)居多(90例,41.5%),用药疗程多≤10 d(159例,73.3%)。抗病毒治疗方案以LPV/r单用(125例,57.6%)或联合阿比多尔(71例,32.7%)为主。结论重症COVID-19患者治疗期间LPV/r使用疗程、剂量、联合用药基本符合指南或文献推荐,但仍存在3种抗病毒药物联合使用,应关注用药安全性与合理性。

Objective To assess the clinical application of lopinavir/ritonavir(LPV/r)in patients with severe coronavirus disease 2019(COVID-19),and to provide references for future clinical practice.Methods The medical records of patients who treated with LPV/r in a designated hospital for severe COVID-19 in February 2020 were retrospectively collected.The patients’demographic characteristics,dosage,timing,course of treatment,combined medication and adverse reactions were statistically analyzed.Results A total of 217 patients received LPV/r during the monitoring period,and most of them were older than 64(90 cases,41.5%).The course of LPV/r was usually within 10 days(159 cases,73.3%).Antiviral treatment regiments were mainly LPV/r alone(125 cases,57.6%)or combined with arbidol(71 cases,32.7%).Conclusion The treatment course,dose and antiviral combination of LPV/r during the treatment of COVID-19 generally met the recommendations of guidelines and literature.However,there were still cases of three kinds of antiviral drugs used in combination,the safety and rationality of LPV/r use should be extensively concerned.